Safety of measles, mumps, and rubella vaccine in adolescents and adults in the vaccine safety Datalink.
ACIP, Advisory Committee on Immunization Practices
Adolescents
Adults
CDC, Centers for Disease Control and Prevention
CI, confidence interval
ED, emergency department
GBS, Guillain-Barré syndrome
ICD-10-CM, International Classification of Diseases, 10th Revision, Clinical Modification
ICD-9-CM, International Classification of Diseases, 9th Revision, Clinical Modification
IQR, interquartile range
ITP, immune thrombocytopenia
MMR
MMR, measles, mumps, and rubella vaccine
MMRV, measles, mumps, rubella, and varicella vaccine
RR, relative risk
SCRI, self-controlled risk interval
Safety
VAERS, Vaccine Adverse Event Reporting System
VSD, Vaccine Safety Datalink
Vaccine
Journal
Vaccine: X
ISSN: 2590-1362
Titre abrégé: Vaccine X
Pays: England
ID NLM: 101748769
Informations de publication
Date de publication:
Apr 2023
Apr 2023
Historique:
received:
15
06
2022
revised:
13
12
2022
accepted:
01
02
2023
entrez:
23
2
2023
pubmed:
24
2
2023
medline:
24
2
2023
Statut:
epublish
Résumé
Measles, mumps, and rubella vaccine (MMR) is routinely administered to children; however, adolescents and adults may receive MMR for various reasons. Safety studies in adolescents and adults are limited. We report on safety of MMR in this age group in the Vaccine Safety Datalink. We included adolescents (aged 9-17 years) and adults (aged ≥ 18 years) who received ≥ 1 dose of MMR from January 1, 2010-December 31, 2018. Pre-specified outcomes were identified by diagnosis codes. Clinically serious outcomes included anaphylaxis, encephalitis/myelitis, Guillain-Barré syndrome, immune thrombocytopenia, meningitis, and seizure. Non-serious outcomes were allergic reaction, arthropathy, fever, injection site reaction, lymphadenopathy, non-specific reaction, parotitis, rash, and syncope. All serious outcomes underwent medical record review. Outcome-specific incidence was calculated in pre-defined post-vaccination windows. A self-controlled risk interval design was used to determine the relative risk of each outcome in a risk window after vaccination compared to a more distal control window. During the study period, 276,327 MMR doses were administered to adolescents and adults. Mean age of vaccinees was 34.8 years; 65.8 % were female; 53.2 % of doses were administered simultaneously with ≥ 1 other vaccine. Serious outcomes were rare, with incidence ≤ 6 per 100,000 doses for each outcome assessed, and none had a significant elevation in incidence during the risk window compared to the control window. Incidence of non-serious outcomes per 100,000 doses ranged from 3.4 for parotitis to 263.0 for arthropathy. Other common outcomes included injection site reaction and rash (157.0 and 112.9 per 100,000 doses, respectively). Significantly more outcomes were observed during the risk window compared to the control window for all non-serious outcomes except parotitis. Some variability was observed by sex and age group. Serious outcomes after MMR are rare in adolescents and adults, but vaccinees should be counseled regarding anticipated local and systemic non-serious adverse events.
Sections du résumé
Background
UNASSIGNED
Measles, mumps, and rubella vaccine (MMR) is routinely administered to children; however, adolescents and adults may receive MMR for various reasons. Safety studies in adolescents and adults are limited. We report on safety of MMR in this age group in the Vaccine Safety Datalink.
Methods
UNASSIGNED
We included adolescents (aged 9-17 years) and adults (aged ≥ 18 years) who received ≥ 1 dose of MMR from January 1, 2010-December 31, 2018. Pre-specified outcomes were identified by diagnosis codes. Clinically serious outcomes included anaphylaxis, encephalitis/myelitis, Guillain-Barré syndrome, immune thrombocytopenia, meningitis, and seizure. Non-serious outcomes were allergic reaction, arthropathy, fever, injection site reaction, lymphadenopathy, non-specific reaction, parotitis, rash, and syncope. All serious outcomes underwent medical record review. Outcome-specific incidence was calculated in pre-defined post-vaccination windows. A self-controlled risk interval design was used to determine the relative risk of each outcome in a risk window after vaccination compared to a more distal control window.
Results
UNASSIGNED
During the study period, 276,327 MMR doses were administered to adolescents and adults. Mean age of vaccinees was 34.8 years; 65.8 % were female; 53.2 % of doses were administered simultaneously with ≥ 1 other vaccine. Serious outcomes were rare, with incidence ≤ 6 per 100,000 doses for each outcome assessed, and none had a significant elevation in incidence during the risk window compared to the control window. Incidence of non-serious outcomes per 100,000 doses ranged from 3.4 for parotitis to 263.0 for arthropathy. Other common outcomes included injection site reaction and rash (157.0 and 112.9 per 100,000 doses, respectively). Significantly more outcomes were observed during the risk window compared to the control window for all non-serious outcomes except parotitis. Some variability was observed by sex and age group.
Conclusion
UNASSIGNED
Serious outcomes after MMR are rare in adolescents and adults, but vaccinees should be counseled regarding anticipated local and systemic non-serious adverse events.
Identifiants
pubmed: 36814595
doi: 10.1016/j.jvacx.2023.100268
pii: S2590-1362(23)00009-8
pmc: PMC9939709
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100268Informations de copyright
© 2023 The Author(s).
Références
Pediatrics. 2008 Mar;121(3):e687-92
pubmed: 18310189
Vaccine. 2022 Jan 31;40(5):752-756
pubmed: 34980508
MMWR Recomm Rep. 2013 Jun 14;62(RR-04):1-34
pubmed: 23760231
Pediatrics. 2006 Oct;118(4):1422-30
pubmed: 17015532
Pediatrics. 2015 Feb;135(2):e321-9
pubmed: 25560438
Pediatr Infect Dis J. 2013 Apr;32(4):374-80
pubmed: 23099425
Am J Dis Child. 1969 Aug;118(2):237-43
pubmed: 4893824
Clin Infect Dis. 2015 May 15;60(10):e58-65
pubmed: 25637587
N Engl J Med. 2001 Aug 30;345(9):656-61
pubmed: 11547719
Vaccine. 2020 Jan 16;38(3):444-459
pubmed: 31711676
J Travel Med. 2021 Dec 29;28(8):
pubmed: 34101817
Clin Infect Dis. 2021 Oct 5;73(7):e1546-e1553
pubmed: 32766827
J Biopharm Stat. 2016;26(4):686-93
pubmed: 26098696
MMWR Morb Mortal Wkly Rep. 2018 Jan 12;67(1):33-38
pubmed: 29324728
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
J Biom Biostat. 2012 Apr 19;Suppl 7:006
pubmed: 24707443
Vaccine. 1991 May;9(5):297-9
pubmed: 1872012
Int J Adolesc Med Health. 2006 Oct-Dec;18(4):615-22
pubmed: 17340852
J Infect Dis. 2020 Mar 2;221(6):902-909
pubmed: 31112277
Pediatrics. 2011 May;127 Suppl 1:S45-53
pubmed: 21502240
Cochrane Database Syst Rev. 2021 Nov 22;11:CD004407
pubmed: 34806766
Pediatr Infect Dis J. 2021 Nov 1;40(11):1046-1054
pubmed: 34310506
MMWR Morb Mortal Wkly Rep. 2001 Nov 9;50(44):976-9
pubmed: 11724151
Hum Vaccin Immunother. 2022 Dec 31;18(1):1-7
pubmed: 34128759
J Biomed Inform. 2019 Jul;95:103208
pubmed: 31078660
Vaccine. 2012 Nov 19;30(49):7052-8
pubmed: 23041123
Am J Dis Child. 1969 Aug;118(2):218-25
pubmed: 5794817